Antoni Chan MD (Prof) synovialjoints
3 months 3 weeks ago
Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026
Mrinalini Dey DrMiniDey
3 months 3 weeks ago
#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 3 weeks ago
#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB
Mrinalini Dey DrMiniDey
3 months 3 weeks ago
#OP006 - Urine proteomics in LN tracks histo activity & treatment response better than proteinuria. Paired biopsies linked active disease to IFNI, IL12, complement & neut pathways- normalised in responders but persisted in non-responders. @RheumNow #EULAR2026 #EULARBest #Plenary
Md Yuzaiful Md Yusof Yuz6Yusof
3 months 3 weeks ago
#EULAR2026 Please find my video interview with Prof Xavier Mariette, the presenting author of Abstract OP0126: Efficacy and Safety of Ianalumab in #Sjogren disease #SjD @RheumNow
https://t.co/NEyBOD6Qj2 https://t.co/Zn1fH6eu39
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr?
Phase2b/3 RCT: ~50% ACR50 at week in 343pts
OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
🔬 Does synovial biopsy-guided treatment outperform standard care in PsA?
YES - 68% vs 45% DAPSA remission/LDA in 45pts
OP071 #EULAR2026 @RheumNow https://t.co/cLCR7I8QAm
Janet Pope Janetbirdope
3 months 3 weeks ago
#Rosnilimab works!! #PD1 agonist
In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis
Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA
#EULAR2026 @RheumNow
#OP0202 #EULARbest https://t.co/Jz92npXdgd
Aurelie Najm AurelieRheumo
3 months 3 weeks ago
SUNSTAR head-to-head after failure of 1 (80+%)–2 prior b/tsDMARDs in RA TCZ vs. ABA
Confirms what we already knew:
-Primary endpoint CDAI change wk26 not different
-Composite response (persistence + low disease activity + low steroid use) 51% vs 35% p=0.034
-Better response in https://t.co/002n3sWtKs
Antoni Chan MD (Prof) synovialjoints
3 months 3 weeks ago
Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints
3 months 3 weeks ago
Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow
Nelly ZIADE 🍀 Nellziade
3 months 3 weeks ago
🤰What happens to RA disease activity during pregnancy?
🔴 Most remain stable
🔴 70% with high disease activity at baseline improve
🔴 20% flare again post-partum
✨ACPA+ improve more
✨ Better outcomes after 2016 (after modern treatments)
OP0242 #EULAR2025 @rheumnow https://t.co/i3X566DcN6
Dr. John Cush RheumNow
3 months 3 weeks ago
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
sheila RHEUMarampa
3 months 3 weeks ago
Roc-SpA study
Active axSpA dse + inad response to TNFi ➡️switch or cycled
No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi
Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi
Shared decision is key
AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv
